"That pan-tumor approval and this patient case really highlight that in prostate cancer, we should be checking HER2 by immunohistochemistry," says Maneesh R. Jain, MD.

Patients with high P-CARE scores had an increased risk of any, metastatic, and fatal prostate cancer compared with patients with median P-CARE scores.

TAR-200 is an intravesical gemcitabine-releasing system for BCG-unresponsive NMIBC, evaluated in the SunRISe-1 trial. The trial's focus was on TAR-200 monotherapy, with other cohorts including ...

"The durability response for these patients was impressive given the fact that these patients were those who, by definition and by inclusion criteria, were recurrent within a year at [baseline]," says ...

Focal ablation for radiorecurrent localized prostate cancer shows favorable functional outcomes compared to salvage radical prostatectomy. Current studies on salvage focal ablation are limited, but ...

Two-thirds of patients with a complete response at three months avoided cystectomy at 60 months. Among cystectomy patients, only six progressed to muscle-invasive bladder cancer, indicating low ...

“The median DOR of 47.8 months in patients who achieved complete response with JELMYTO provides evidence of robust durability in maintaining control of low-grade UTUC over an extended period,” says ...

"There's a ton of activity in this space, and I think every 6 to 12 months, we're going to keep getting these boluses of information that's going to help us," says Gautam Jayram, MD.

BCG-exposed non-muscle invasive bladder cancer patients often relapse, highlighting the need for effective combination therapies to prevent disease progression. Current BCG combinations with immune ...

Nadofaragene firadenovec offers a 66% probability of cystectomy-free survival at 60 months for BCG-unresponsive NMIBC with CIS ± Ta/T1 disease. The phase 3 study enrolled 107 patients, with 103 ...

"Most of the AEs were grade 1 and 2. These consisted of frequency, urgency, UTIs—again, things we're very used to with intravesical therapies," says Siamak Daneshmand, MD.